App-Quantinova.ai

Rhesus Macaques As Natural Models for Age-Related Clonal Hematopoiesis

Yifan Zhou - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

N/A

A Novel Human Fetal Model of CRISPR-Cas9-Induced MLL-AF4 Leukemia Faithfully Recapitulates Infant ALL and Can be Used to Unravel MLL-AF4 Function

Siobhan Rice - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Overcoming Multidrug Resistance in B Cell Malignancies By Antagonism of Stromal Mediated TGF-β Signalling

Eugene Park - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Venetoclax

Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Morten P Oksvold - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

TP53

Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Dirk Reinhardt - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to Venetoclax

Klaudyna Fidyt - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Venetoclax

Intention to Treat Analysis of Real-World Outcomes Following Tisgenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme

Sara Ghorashian - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

tisagenlecleucel-t

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Thomas Moehler - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

CC-486

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Silvia Maifrede - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

L-Tyrosine

Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Christopher J. Hindley - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

L-Tyrosine

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

gilteritinib

Investigating the Dual Targeting of BCL-2 and CD38 in Models of Acute Myeloid Leukemia

Jayna J Mistry - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

daratumumab Intravenous

Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Romy E. Van Weelderen - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Harmony Alliance Provides Novel Insights into Acute Myeloid Leukemia Based on a Pan-European NGS Data Collection

Lars Bullinger - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study

Matthew J Cross - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

N/A

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Lale Kostakoglu - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Obinutuzumab

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Larry W. Kwak - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Rituximab

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Ibrahim Tohidi-Esfahani - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Waldenstrom’s macroglobulinemia

N/A

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Gilles Salles - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Multifocal leukoencephalopathy

Idelalisib

Filters

45280 Abstracts